Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report.

Proboka G, Rasa A, Olmane E, Isajevs S, Tilgase A, Alberts P.

Medicine (Baltimore). 2019 Nov;98(45):e17883. doi: 10.1097/MD.0000000000017883.

2.

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient.

Brokāne L, Jaunalksne I, Tilgase A, Olmane E, Petroška D, Rasa A, Alberts P.

Clin Case Rep. 2019 May 8;7(6):1191-1196. doi: 10.1002/ccr3.2182. eCollection 2019 Jun.

3.

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®.

Ismailov Z, Rasa A, Bandere K, Brokāne L, Tilgase A, Olmane E, Nazarovs J, Alberts P.

Am J Case Rep. 2019 Jan 12;20:48-52. doi: 10.12659/AJCR.912115.

4.

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery.

Tilgase A, Olmane E, Nazarovs J, Brokāne L, Erdmanis R, Rasa A, Alberts P.

Case Rep Gastroenterol. 2018 Aug 23;12(2):457-465. doi: 10.1159/000492210. eCollection 2018 May-Aug.

5.

The advent of oncolytic virotherapy in oncology: The Rigvir® story.

Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D.

Eur J Pharmacol. 2018 Oct 15;837:117-126. doi: 10.1016/j.ejphar.2018.08.042. Epub 2018 Sep 1. Review.

6.

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro.

Tilgase A, Patetko L, Blāķe I, Ramata-Stunda A, Borodušķis M, Alberts P.

J Cancer. 2018 Feb 28;9(6):1033-1049. doi: 10.7150/jca.23242. eCollection 2018.

7.

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report.

Proboka G, Tilgase A, Isajevs S, Rasa A, Alberts P.

Front Oncol. 2018 Feb 26;8:43. doi: 10.3389/fonc.2018.00043. eCollection 2018. Erratum in: Front Oncol. 2018 May 18;8:172.

8.

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports.

Alberts P, Olmane E, Brokāne L, Krastiņa Z, Romanovska M, Kupčs K, Isajevs S, Proboka G, Erdmanis R, Nazarovs J, Venskus D.

APMIS. 2016 Oct;124(10):896-904. doi: 10.1111/apm.12576. Epub 2016 Jul 26.

PMID:
27457663
9.

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.

Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A.

Melanoma Res. 2015 Oct;25(5):421-6. doi: 10.1097/CMR.0000000000000180.

10.

Tyrosine phosphorylation of NEDD4 activates its ubiquitin ligase activity.

Persaud A, Alberts P, Mari S, Tong J, Murchie R, Maspero E, Safi F, Moran MF, Polo S, Rotin D.

Sci Signal. 2014 Oct 7;7(346):ra95. doi: 10.1126/scisignal.2005290.

PMID:
25292214
11.

A strategy for modulation of enzymes in the ubiquitin system.

Ernst A, Avvakumov G, Tong J, Fan Y, Zhao Y, Alberts P, Persaud A, Walker JR, Neculai AM, Neculai D, Vorobyov A, Garg P, Beatty L, Chan PK, Juang YC, Landry MC, Yeh C, Zeqiraj E, Karamboulas K, Allali-Hassani A, Vedadi M, Tyers M, Moffat J, Sicheri F, Pelletier L, Durocher D, Raught B, Rotin D, Yang J, Moran MF, Dhe-Paganon S, Sidhu SS.

Science. 2013 Feb 1;339(6119):590-5. doi: 10.1126/science.1230161. Epub 2013 Jan 3.

12.

EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin.

Sakariassen KS, Femia EA, Daray FM, Podda GM, Razzari C, Pugliano M, Errasti AE, Armesto AR, Nowak W, Alberts P, Meyer JP, Sorensen AS, Cattaneo M, Rothlin RP.

Thromb Res. 2012 Nov;130(5):746-52. doi: 10.1016/j.thromres.2012.08.309. Epub 2012 Sep 5.

PMID:
22959706
13.

Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation.

Richardson A, Sakariassen KS, Meyer JP, Alberts P, Sorensen AS.

Eur J Clin Pharmacol. 2013 Mar;69(3):459-65. doi: 10.1007/s00228-012-1348-9. Epub 2012 Jul 20.

PMID:
22815050
14.

LAPTM5 protein is a positive regulator of proinflammatory signaling pathways in macrophages.

Glowacka WK, Alberts P, Ouchida R, Wang JY, Rotin D.

J Biol Chem. 2012 Aug 10;287(33):27691-702. doi: 10.1074/jbc.M112.355917. Epub 2012 Jun 25.

15.

Analytical techniques for wine analysis: an African perspective; a review.

de Villiers A, Alberts P, Tredoux AG, Nieuwoudt HH.

Anal Chim Acta. 2012 Jun 12;730:2-23. doi: 10.1016/j.aca.2011.11.064. Epub 2011 Dec 21.

PMID:
22632040
16.

Advanced ultra high pressure liquid chromatography-tandem mass spectrometric methods for the screening of red wine anthocyanins and derived pigments.

Alberts P, Stander MA, de Villiers A.

J Chromatogr A. 2012 Apr 27;1235:92-102. doi: 10.1016/j.chroma.2012.02.058. Epub 2012 Mar 3.

PMID:
22440662
17.

The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.

Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A.

J Thromb Haemost. 2011 Oct;9(10):2109-11. doi: 10.1111/j.1538-7836.2011.04446.x. No abstract available.

18.

Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function.

Persaud A, Alberts P, Hayes M, Guettler S, Clarke I, Sicheri F, Dirks P, Ciruna B, Rotin D.

EMBO J. 2011 Jul 15;30(16):3259-73. doi: 10.1038/emboj.2011.234.

19.

Development of a novel solid-phase extraction, LC-MS/MS method for the analysis of ethyl carbamate in alcoholic beverages: application to South African wine and spirits.

Alberts P, Stander MA, De Villiers A.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011;28(7):826-39. doi: 10.1080/19440049.2011.568010. Epub 2011 May 13.

PMID:
21574082
20.

Regulation of lipid droplet turnover by ubiquitin ligases.

Alberts P, Rotin D.

BMC Biol. 2010 Jul 19;8:94. doi: 10.1186/1741-7007-8-94.

21.

In vivo requirement for Atg5 in antigen presentation by dendritic cells.

Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, Chervonsky A, Mizushima N, Grinstein S, Iwasaki A.

Immunity. 2010 Feb 26;32(2):227-39. doi: 10.1016/j.immuni.2009.12.006. Epub 2010 Feb 18.

22.

Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays.

Persaud A, Alberts P, Amsen EM, Xiong X, Wasmuth J, Saadon Z, Fladd C, Parkinson J, Rotin D.

Mol Syst Biol. 2009;5:333. doi: 10.1038/msb.2009.85. Epub 2009 Dec 1.

23.

Survey of 3-alkyl-2-methoxypyrazine content of South African Sauvignon blanc wines using a novel LC-APCI-MS/MS method.

Alberts P, Stander MA, Paul SO, de Villiers A.

J Agric Food Chem. 2009 Oct 28;57(20):9347-55. doi: 10.1021/jf9026475.

PMID:
19807097
24.

Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.

Sakariassen KS, Alberts P, Fontana P, Mann J, Bounameaux H, Sorensen AS.

Future Cardiol. 2009 Sep;5(5):479-93. doi: 10.2217/fca.09.33. Review.

PMID:
19715412
25.

ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes.

Skogsberg J, Dicker A, Rydén M, Aström G, Nilsson R, Bhuiyan H, Vitols S, Mairal A, Langin D, Alberts P, Walum E, Tegnér J, Hamsten A, Arner P, Björkegren J.

PLoS One. 2008;3(11):e3771. doi: 10.1371/journal.pone.0003771. Epub 2008 Nov 20.

26.

Characterization of energy expenditure in rodents by indirect calorimetry.

Alberts P, Johansson BG, McArthur RA.

Curr Protoc Neurosci. 2006 Aug;Chapter 9:Unit9.23D. doi: 10.1002/0471142301.ns0923ds36.

PMID:
18428652
27.

Fast turnover of L1 adhesions in neuronal growth cones involving both surface diffusion and exo/endocytosis of L1 molecules.

Dequidt C, Danglot L, Alberts P, Galli T, Choquet D, Thoumine O.

Mol Biol Cell. 2007 Aug;18(8):3131-43. Epub 2007 May 30.

28.

Temperature dependence of O2 consumption; opposite effects of leptin and etomoxir on respiratory quotient in mice.

Högberg H, Engblom L, Ekdahl A, Lidell V, Walum E, Alberts P.

Obesity (Silver Spring). 2006 Apr;14(4):673-82.

29.

Cdc42 and actin control polarized expression of TI-VAMP vesicles to neuronal growth cones and their fusion with the plasma membrane.

Alberts P, Rudge R, Irinopoulou T, Danglot L, Gauthier-Rouvière C, Galli T.

Mol Biol Cell. 2006 Mar;17(3):1194-203. Epub 2005 Dec 28.

30.

Effect of high-fat diet on KKAy and ob/ob mouse liver and adipose tissue corticosterone and 11-dehydrocorticosterone concentrations.

Alberts P, Rönquist-Nii Y, Larsson C, Klingström G, Engblom L, Edling N, Lidell V, Berg I, Edlund PO, Ashkzari M, Sahaf N, Norling S, Berggren V, Bergdahl K, Forsgren M, Abrahmsén L.

Horm Metab Res. 2005 Jul;37(7):402-7.

PMID:
16034710
31.

Measurement and characterization of energy expenditure as a tool in the development of drugs for metabolic diseases, such as obesity and diabetes.

Alberts P, Johansson BG, McArthur RA.

Curr Protoc Pharmacol. 2005 Apr;Chapter 5:Unit5.39. doi: 10.1002/0471141755.ph0539s28.

PMID:
21953391
32.

Regulation of 11beta-hydroxysteroid dehydrogenase type 1 and glucose-stimulated insulin secretion in pancreatic islets of Langerhans.

Ortsäter H, Alberts P, Warpman U, Engblom LO, Abrahmsén L, Bergsten P.

Diabetes Metab Res Rev. 2005 Jul-Aug;21(4):359-66.

PMID:
15586384
33.

Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.

Weisshorn R, Wappler F, Fiege M, Gerbershagen MU, Kolodzie K, Alberts P, Horn EP, Schulte Am Esch J.

J Clin Anesth. 2004 Aug;16(5):353-7.

PMID:
15374556
34.
35.

Tetanus neurotoxin-insensitive vesicle-associated membrane protein localizes to a presynaptic membrane compartment in selected terminal subsets of the rat brain.

Muzerelle A, Alberts P, Martinez-Arca S, Jeannequin O, Lafaye P, Mazié JC, Galli T, Gaspar P.

Neuroscience. 2003;122(1):59-75.

PMID:
14596849
36.

Cross talk between tetanus neurotoxin-insensitive vesicle-associated membrane protein-mediated transport and L1-mediated adhesion.

Alberts P, Rudge R, Hinners I, Muzerelle A, Martinez-Arca S, Irinopoulou T, Marthiens V, Tooze S, Rathjen F, Gaspar P, Galli T.

Mol Biol Cell. 2003 Oct;14(10):4207-20. Epub 2003 Jun 27.

37.

Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.

Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingström G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, Abrahmsen LB.

Endocrinology. 2003 Nov;144(11):4755-62. Epub 2003 Jul 31.

PMID:
12960099
38.

Ectopic expression of syntaxin 1 in the ER redirects TI-VAMP- and cellubrevin-containing vesicles.

Martinez-Arca S, Proux-Gillardeaux V, Alberts P, Louvard D, Galli T.

J Cell Sci. 2003 Jul 1;116(Pt 13):2805-16. Epub 2003 May 20.

39.

Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.

Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Ohman B, Abrahmsén L.

Diabetologia. 2002 Nov;45(11):1528-32. Epub 2002 Sep 18.

PMID:
12436336
40.

Characterization of a new muscarinic receptor antagonist PNU-171990 in guinea pig, cat and human smooth muscle.

Modiri AR, Vasänge M, Alberts P, Jossan SS, Sundquist S, Gillberg PG.

Eur J Pharmacol. 2002 Sep 13;451(2):171-5.

PMID:
12231388
41.

Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

Barf T, Vallgårda J, Emond R, Häggström C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Rönquist-Nii Y, Ohman B, Alberts P, Abrahmsén L.

J Med Chem. 2002 Aug 29;45(18):3813-5.

PMID:
12190302
42.
43.

In vitro effects of 4-chloro-3-ethylphenol in skeletal muscle preparations from malignant hyperthermia susceptible and normal swine.

Gerbershagen MU, Wappler F, Fiege M, Weilsshorn R, Alberts PA, von Breunig F, Schulte am Esch J.

Eur J Anaesthesiol. 2002 Feb;19(2):135-40.

PMID:
11999597
44.

A common exocytotic mechanism mediates axonal and dendritic outgrowth.

Martinez-Arca S, Coco S, Mainguy G, Schenk U, Alberts P, Bouillé P, Mezzina M, Prochiantz A, Matteoli M, Louvard D, Galli T.

J Neurosci. 2001 Jun 1;21(11):3830-8.

45.

Distinct functional properties of the TAP subunits coordinate the nucleotide-dependent transport cycle.

Alberts P, Daumke O, Deverson EV, Howard JC, Knittler MR.

Curr Biol. 2001 Feb 20;11(4):242-51.

46.

Clostridial neurotoxin-insensitive vesicular SNAREs in exocytosis and endocytosis.

Martinez-Arca S, Alberts P, Galli T.

Biol Cell. 2000 Sep;92(6):449-53. Review. No abstract available.

PMID:
11132707
47.

In vitro alpha-adrenoceptor autoradiography of the urethra and urinary bladder of the female pig, cat, guinea-pig and rat.

Monneron MC, Gillberg PG, Ohman B, Alberts P.

Scand J Urol Nephrol. 2000 Aug;34(4):233-8.

PMID:
11095080
48.

Selectivity of oxymetazoline for urethral pressure vs blood pressure in the anaesthetized female rabbit.

Modiri AR, Fredrickson MG, Gillberg PG, Alberts P.

Scand J Urol Nephrol. 2000 Jun;34(3):151-6.

PMID:
10961466
49.

Role of tetanus neurotoxin insensitive vesicle-associated membrane protein (TI-VAMP) in vesicular transport mediating neurite outgrowth.

Martinez-Arca S, Alberts P, Zahraoui A, Louvard D, Galli T.

J Cell Biol. 2000 May 15;149(4):889-900.

50.

Nucleotide binding by TAP mediates association with peptide and release of assembled MHC class I molecules.

Knittler MR, Alberts P, Deverson EV, Howard JC.

Curr Biol. 1999 Sep 23;9(18):999-1008.

Supplemental Content

Loading ...
Support Center